Related Jobs
-
Senior Clinical Research Associate
Job Type: Permanent
Salary: € 30000.00 per annum
Location: Croatia -
Senior Regulatory Executive - Leading Consumer Brands
Job Type: Permanent
Salary: Salary on application
Location: England - Berkshire
Exenatide 'as effective' as insulin says Eli Lilly
15 Sep 2006
Clinical Research
New research released yesterday shows that exenatide is as effective as insulin in controlling blood sugar levels, according to parent company Eli Lilly.
The trial ran for a full year, during which patients on exenatide showed – on average – weight loss, as well as improvements in fasting blood glucose, postprandial blood glucose and haemoglobin A1C (HbA1C) levels.
A third (32 per cent) of those receiving the treatment met the target of a HbA1C level of seven per cent or less; 18 per cent of exenatide patients managed an HbA1C level of 6.5 per cent or less, compared with nine per cent of those receiving standard diabetes treatments as part of the trial.
Professor Michael Nauck, a study author and director of the Diabetes Centre in Bad Lauterberg, Germany, said: "This comparator study demonstrates that exenatide has similar blood glucose control to the conventional treatment with insulin.
"These data show that exenatide, without the inconvenience of dose titration, is a potential alternative to biphasic insulin aspart for the treatment of patients with type 2 diabetes not adequately treated with metformin and a sulfonylurea, commonly used oral antidiabetic agents," he added.
Exenatide belongs to a class of drugs called incretin mimetics, and received its regulatory approval last April in the US; it is injected twice daily.
© Adfero Ltd
